BioCryst Pharmaceuticals, Inc.

Good day, everyone, and thank you for standing by. Welcome to the Biochrist fourth quarter 2021 earnings call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will host a question-answer session, and our instructions will be given at that time. If during your conference today you do require operator assistance, please press star then zero, and an operator will be happy to assist you. As a reminder, this conference call is being recorded. It is now my pleasure to hand the conference over to Mr. John Bluth with Biochrist. Please proceed.

Thanks, Brian. Good morning and welcome to BioCHRIS fourth quarter 2021 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO John Stonehouse, CFO Anthony Doyle, Chief Commercial Officer Charlie Geyer, and Chief R&D Officer Dr. Helen Thackeray. Following our remarks, we will answer your questions. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. I'd now like to turn the call over to John Stonehouse.

Thanks, John. 2021 was a great success for Biochris as we took a big step forward toward our goal of building the next great biotech company. The launch of our first oral drug for rare disease patients suffering from HAE or Ladeo got off to a tremendous start. with $122.6 million of net revenue in the first year, we have a solid base to build off. That led us to confidently guide you to no less than $250 million this year and $1 billion in global peak sales. Patients want an oral therapy, and we are on our way to becoming the market leader in the prophylactic treatment of HAE. But oral adeo is just the beginning. In 2021, we also advanced our pipeline that will lead to significant additional value creation. Our oral factor D inhibitor, B69930, moved from a phase one in one indication to pivotal studies in P and H and a proof of concept study in three renal indications. What's important to note here is not only do we have a late stage program on the heels of the approval and launch of oral adeo, but this molecule has the potential to be an entire pipeline. Imagine having filings for major approvals, additional pivotal programs, and many proof-of-concept studies in many different rare diseases. That's what we have with 9930, and we're allocating our capital into this program to compound value for years to come. And finally, late last year, we brought in significant additional capital that gives us the ability to retain the rights of these programs and create greater value for our shareholders. So 2022 is another year focused on executing our plan, continuing to grow Orladeo in the U.S. and around the world, and advancing our pipeline, enrolling pivotal and proof-of-concept studies, all to increase in compound value. It is an exciting time at Biochrist. Now I'll turn the call over to Charlie for more details on the Orladeo launch.